136 related articles for article (PubMed ID: 36204890)
1. A novel targeted iron oxide nanocarrier for inhibiting M2-type macrophages in the tumor microenvironment.
Tian K; Feng R; Wang X; Wu X; Li L; Liu W; Wu R
J Cancer Res Ther; 2022 Sep; 18(5):1409-1416. PubMed ID: 36204890
[TBL] [Abstract][Full Text] [Related]
2. Targeting the Stat6 pathway in tumor-associated macrophages reduces tumor growth and metastatic niche formation in breast cancer.
Binnemars-Postma K; Bansal R; Storm G; Prakash J
FASEB J; 2018 Feb; 32(2):969-978. PubMed ID: 29066614
[TBL] [Abstract][Full Text] [Related]
3. Pulsatilla Saponins Inhibit Experimental Lung Metastasis of Melanoma via Targeting STAT6-Mediated M2 Macrophages Polarization.
Yang X; Wu M; Yan X; Zhang C; Luo Y; Yu J
Molecules; 2023 Apr; 28(9):. PubMed ID: 37175092
[No Abstract] [Full Text] [Related]
4. Gefitinib inhibits M2-like polarization of tumor-associated macrophages in Lewis lung cancer by targeting the STAT6 signaling pathway.
Tariq M; Zhang JQ; Liang GK; He QJ; Ding L; Yang B
Acta Pharmacol Sin; 2017 Nov; 38(11):1501-1511. PubMed ID: 29022575
[TBL] [Abstract][Full Text] [Related]
5. Exosome-mediated genetic reprogramming of tumor-associated macrophages by exoASO-STAT6 leads to potent monotherapy antitumor activity.
Kamerkar S; Leng C; Burenkova O; Jang SC; McCoy C; Zhang K; Dooley K; Kasera S; Zi T; Sisó S; Dahlberg W; Sia CL; Patel S; Schmidt K; Economides K; Soos T; Burzyn D; Sathyanarayanan S
Sci Adv; 2022 Feb; 8(7):eabj7002. PubMed ID: 35179953
[TBL] [Abstract][Full Text] [Related]
6. Blocking Interleukin (IL)4- and IL13-Mediated Phosphorylation of STAT6 (Tyr641) Decreases M2 Polarization of Macrophages and Protects Against Macrophage-Mediated Radioresistance of Inflammatory Breast Cancer.
Rahal OM; Wolfe AR; Mandal PK; Larson R; Tin S; Jimenez C; Zhang D; Horton J; Reuben JM; McMurray JS; Woodward WA
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):1034-1043. PubMed ID: 29485045
[TBL] [Abstract][Full Text] [Related]
7. CD137 signaling induces macrophage M2 polarization in atherosclerosis through STAT6/PPARδ pathway.
Geng T; Yan Y; Xu L; Cao M; Xu Y; Pu J; Yan JC
Cell Signal; 2020 Aug; 72():109628. PubMed ID: 32247042
[TBL] [Abstract][Full Text] [Related]
8. Nanotherapy delivery of c-myc inhibitor targets Protumor Macrophages and preserves Antitumor Macrophages in Breast Cancer.
Esser AK; Ross MH; Fontana F; Su X; Gabay A; Fox GC; Xu Y; Xiang J; Schmieder AH; Yang X; Cui G; Scott M; Achilefu S; Chauhan J; Fletcher S; Lanza GM; Weilbaecher KN
Theranostics; 2020; 10(17):7510-7526. PubMed ID: 32685002
[TBL] [Abstract][Full Text] [Related]
9. MFHAS1 promotes colorectal cancer progress by regulating polarization of tumor-associated macrophages via STAT6 signaling pathway.
Chen W; Xu Y; Zhong J; Wang H; Weng M; Cheng Q; Wu Q; Sun Z; Jiang H; Zhu M; Ren Y; Xu P; Chen J; Miao C
Oncotarget; 2016 Nov; 7(48):78726-78735. PubMed ID: 27783989
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD206 antibody-conjugated Fe
Zhou Y; Que KT; Tang HM; Zhang P; Fu QM; Liu ZJ
Oncol Lett; 2020 Dec; 20(6):298. PubMed ID: 33101492
[TBL] [Abstract][Full Text] [Related]
11. Pyropia yezoensis glycoprotein promotes the M1 to M2 macrophage phenotypic switch via the STAT3 and STAT6 transcription factors.
Choi JW; Kwon MJ; Kim IH; Kim YM; Lee MK; Nam TJ
Int J Mol Med; 2016 Aug; 38(2):666-74. PubMed ID: 27353313
[TBL] [Abstract][Full Text] [Related]
12. STAT3 inhibition specifically in human monocytes and macrophages by CD163-targeted corosolic acid-containing liposomes.
Andersen MN; Etzerodt A; Graversen JH; Holthof LC; Moestrup SK; Hokland M; Møller HJ
Cancer Immunol Immunother; 2019 Mar; 68(3):489-502. PubMed ID: 30637473
[TBL] [Abstract][Full Text] [Related]
13. Major vault protein regulates tumor-associated macrophage polarization through interaction with signal transducer and activator of transcription 6.
Yu C; Zhu Q; Ma C; Luo C; Nie L; Cai H; Wang Q; Wang F; Ren H; Yan H; Xu K; Zhou L; Zhang C; Lu G; Lu Z; Zhu Y; Liu S
Front Immunol; 2023; 14():1289795. PubMed ID: 38264642
[TBL] [Abstract][Full Text] [Related]
14. Ketone body β-hydroxybutyrate ameliorates colitis by promoting M2 macrophage polarization through the STAT6-dependent signaling pathway.
Huang C; Wang J; Liu H; Huang R; Yan X; Song M; Tan G; Zhi F
BMC Med; 2022 Apr; 20(1):148. PubMed ID: 35422042
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of STAT6 Activation by AS1517499 Inhibits Expression and Activity of PPARγ in Macrophages to Resolve Acute Inflammation in Mice.
Lee YJ; Kim K; Kim M; Ahn YH; Kang JL
Biomolecules; 2022 Mar; 12(3):. PubMed ID: 35327639
[TBL] [Abstract][Full Text] [Related]
16. S100A4 enhances protumor macrophage polarization by control of PPAR-γ-dependent induction of fatty acid oxidation.
Liu S; Zhang H; Li Y; Zhang Y; Bian Y; Zeng Y; Yao X; Wan J; Chen X; Li J; Wang Z; Qin Z
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34145030
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and evaluation of multivalent M2pep peptides for targeting alternatively activated M2 macrophages.
Ngambenjawong C; Cieslewicz M; Schellinger JG; Pun SH
J Control Release; 2016 Feb; 224():103-111. PubMed ID: 26772876
[TBL] [Abstract][Full Text] [Related]
18. Polarization of tumor-associated macrophage phenotype via porous hollow iron nanoparticles for tumor immunotherapy in vivo.
Li K; Lu L; Xue C; Liu J; He Y; Zhou J; Xia Z; Dai L; Luo Z; Mao Y; Cai K
Nanoscale; 2020 Jan; 12(1):130-144. PubMed ID: 31799577
[TBL] [Abstract][Full Text] [Related]
19. M2-Like Tumor-Associated Macrophage-Targeted Codelivery of STAT6 Inhibitor and IKKβ siRNA Induces M2-to-M1 Repolarization for Cancer Immunotherapy with Low Immune Side Effects.
Xiao H; Guo Y; Li B; Li X; Wang Y; Han S; Cheng D; Shuai X
ACS Cent Sci; 2020 Jul; 6(7):1208-1222. PubMed ID: 32724855
[TBL] [Abstract][Full Text] [Related]
20. Impact of Surface Chemistry of Ultrasmall Superparamagnetic Iron Oxide Nanoparticles on Protein Corona Formation and Endothelial Cell Uptake, Toxicity, and Barrier Function.
Diaz-Diestra DM; Palacios-Hernandez T; Liu Y; Smith DE; Nguyen AK; Todorov T; Gray PJ; Zheng J; Skoog SA; Goering PL
Toxicol Sci; 2022 Jul; 188(2):261-275. PubMed ID: 35708658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
